Popular mammography tool not effective for finding invasive breast cancer
Computer-aided detection (CAD) technology is ineffective in finding breast tumors, and appears to increase a woman’s risk of being called back needlessly for additional testing following mammography, a large UC Davis study has found.
The analysis of 1.6 million mammograms in seven states has delivered the most definitive findings to date on whether the popular mammography tool is effective in helping find breast cancer.
"In real-world practice, CAD increases the chances of being unnecessarily called back for further testing because of false-positive results without clear benefits to women,” said Joshua Fenton, assistant professor in the UC Davis Department of Family and Community Medicine. “Breast cancers were detected at a similar stage and size regardless of whether or not radiologists used CAD."
The study examined screening mammograms performed on more than 680,000 women at 90 mammography facilities in seven U.S. states from 1998 to 2006. The false-positive rate typically increased from 8.1 percent before CAD to 8.6 percent after CAD was installed at the facilities in the study. In addition, the detection rate of breast cancer and the stage and size of breast cancer tumors were similar regardless of CAD. The study, entitled “Effectiveness of Computer-Aided Detection in Community Mammography Practice,” was published online today in the Journal of the National Cancer Institute and used data from the Breast Cancer Surveillance Consortium.
Computer-aided detection software, approved by the Food and Drug Administration in 1998, analyzes the mammogram image and marks suspicious areas for radiologists to review. Its use has skyrocketed in recent years since Medicare began covering it in 2001. CAD is now applied to the large majority of screening mammograms in the U.S. with annual direct Medicare costs exceeding $30 million, according to a 2010 study in the Journal of the American College of Radiology.
According to 2009 Medicare data, insurers including Medicare typically paid about $12 per screening mammogram for CAD in addition to the costs of the mammogram (about $81 for film mammography and $130 for digital mammography), representing a 9 percent to 15 percent additional cost for CAD use.
The current study builds on Fenton’s initial assessment of the technology published in the New England Journal of Medicine in 2007. That report, which examined mammography screening results in 43 facilities, including seven that utilized CAD, found that CAD was associated with reduced accuracy of interpretation of screening mammograms but no difference in the detection rate of invasive breast cancer.
Critics of the research findings in the New England Journal of Medicine said the study was based on use of an older kind of CAD technology, and so did not accurately reflect its usefulness.“In the current study, we evaluated newer technology in a larger sample and over a longer time period,” said Fenton.
“We also looked for the first time at cancer stage and cancer size, which are critical for understanding how CAD may affect long-term breast cancer outcomes, such as mortality.”
The authors write that the results of real-world studies of CAD may differ from results from pre-clinical studies. They suggest that these differences may arise because radiologists in clinical practice don’t always adhere as strictly to use of the technology as designed, as have radiologists in protocol-driven studies.
Fenton’s co-authors are at Group Health Research Institute, Cancer Research and Biostatistics, and the University of Washington, in Seattle; the National Cancer Institute, in Bethesda, MD; University of Vermont, in Burlington; Oregon Health and Science University, in Portland; and Emory University, in Atlanta.
The study was conducted within the national Breast Cancer Surveillance Consortium, which is funded by the National Cancer Institute. Additional support was provided by the American Cancer Society, along with state public health departments and cancer registries throughout the U.S.
Breast Cancer Surveillance Consortium
The Breast Cancer Surveillance Consortium (BCSC) is a research resource for studies designed to assess the delivery and quality of breast cancer screening and related patient outcomes in the United States. The BCSC is a National Cancer Institute-funded collaborative network of seven mammography registries with linkages to tumor and/or pathology registries. The network is supported by a central Statistical Coordinating Center. Currently, the Consortium's database contains information on over 8 million mammographic examinations, 2.3 million women, and 100,000 breast cancer cases (85,000 invasive cancers and 17,000 ductal carcinomas in situ). For more information, visit http://breastscreening.cancer.gov.